Short answer: The Omnitrope label sets a weekly dose by body weight for children, divided over 6 or 7 days of injections under the skin: 0.16 to 0.24 mg/kg/week for growth hormone deficiency, 0.24 for Prader-Willi, up to 0.48 for SGA, 0.33 for Turner and up to 0.47 for idiopathic short stature. Adults start at not more than 0.04 mg/kg/week or about 0.2 mg/day.
This is what the FDA label says. Follow your prescriber. Your prescriber may use a different dose or pace than the label's standard schedule.
What Omnitrope is approved for: Omnitrope is approved for children with growth failure from growth hormone deficiency, Prader-Willi syndrome, being born small for gestational age without catch-up growth by age 2, Turner syndrome, or idiopathic short stature (height SDS of -2.25 or below with open growth plates). It is also approved to replace growth hormone in adults with growth hormone deficiency that began in adulthood or childhood (section 1).
Source
OMNITROPE (somatropin) injection and for injection, for subcutaneous use, prescribing information and Instructions for Use. Sandoz. DailyMed, version published April 1, 2026. DailyMed setid 58d84ffa-4056-4e36-ad67-7bd4aef444a5
The weekly dose is divided over 6 or 7 days of subcutaneous injections. The label says the dose is given daily, preferably in the evening, in the thigh, buttocks or abdomen, and injection sites are always rotated (sections 2 and 2.3).
Omnitrope comes as 5 mg/1.5 mL and 10 mg/1.5 mL cartridges for the Omnitrope Pen 5 and Pen 10, and as a 5.8 mg vial. It is used only if clear and colorless, and kept refrigerated at 2° to 8°C (36° to 46°F) (section 2.3).
The label says an Omnitrope Pen should never be shared with another person, even if the needle is changed (section 17).
The table below is the label's schedule, from the Dosage and Administration section. Numbers are copied exactly; the section is in brackets.
| Condition | Dose on the label |
|---|---|
| Pediatric growth hormone deficiency (GHD) | 0.16 to 0.24 mg/kg body weight/week |
| Prader-Willi Syndrome (PWS) | 0.24 mg/kg body weight/week |
| Small for Gestational Age (SGA) | Up to 0.48 mg/kg body weight/week |
| Turner Syndrome (TS) | 0.33 mg/kg body weight/week |
| Idiopathic Short Stature (ISS) | Up to 0.47 mg/kg of body weight/week |
| Adult GHD, weight-based | Start not more than 0.04 mg/kg/week as a daily injection; may increase at 4- to 8-week intervals to not more than 0.08 mg/kg/week |
| Adult GHD, non-weight dosing | Start approximately 0.2 mg/day (range, 0.15-0.30 mg/day); increase every 1-2 months by approximately 0.1 to 0.2 mg/day |
In children, the dose and schedule are individualized based on growth response. Response tends to decrease over time, but a failure to grow faster, especially in the first year, calls for checking adherence and other causes such as hypothyroidism, undernutrition, advanced bone age or antibodies.
Treatment for short stature is stopped when the growth plates (epiphyses) are fused.
Adult weight-based dosing is guided by clinical response, side effects and age- and gender-adjusted IGF-1 levels. Non-weight dosing is lowered if side effects occur or IGF-1 rises above the age- and gender-specific normal range. Maintenance doses vary considerably from person to person.
Older adults may start lower with smaller increases, since they are more prone to side effects. Obese people are more likely to have side effects on the weight-based regimen. Estrogen-replete women may need higher doses than men, and oral estrogen may increase dose needs.
People treated for growth hormone deficiency as children whose growth plates have closed are re-evaluated before continuing at the lower adult dose.
If somatropin-induced intracranial hypertension is diagnosed, treatment can be restarted at a lower dose once the signs have resolved.
The doses of insulin or oral diabetes drugs may need adjusting when somatropin is started.
The Omnitrope label gives no missed-dose instruction. Ask your prescriber or pharmacist what to do if a dose is missed.
In Dose Track you set up Omnitrope as a protocol with the dose and schedule your prescriber gave you. A protocol can hold dose steps, each with its own dose and length in days or weeks, so a step-up plan like the one on the label can be entered once and the app moves to the next step on its own. Reminders follow the schedule, and every dose is logged with the date and time, so you can see which step you are on and when your last dose was. The app follows what you enter; it does not choose or change a dose.
This page is what the FDA label says, in plain words. It is not medical advice. Follow your prescriber, and ask them or your pharmacist about anything here.